Bluefin Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Bluefin Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13,800	Closed	-$2.02K	–	93
2025 Q2	$2.02K	Buy	+13,800	New	+$677K	﹤0.01%	136
2022 Q4	–	Sell	-10,000	Closed	-$3K	–	525
2022 Q3	$3K	Buy	+10,000	New	+$725K	﹤0.01%	501
2022 Q1	–	Sell	-27,000	Closed	-$1K	–	698
2021 Q4	$1K	Buy	27,000 +2,700	+11%	+$158K	﹤0.01%	879
2021 Q3	$19K	Buy	+24,300	New	+$1.6M	﹤0.01%	623
2020 Q4	–	Hold	0	–	-$1K	–	696
2020 Q3	–	Sell	-85,200	Closed	-$5.13M	–	470
2020 Q2	$30K	Buy	85,200 +5,300	+7%	+$317K	﹤0.01%	321
2020 Q1	$329K	Sell	79,900 -104,500	-57%	-$6.39M	0.04%	208
2019 Q4	$8K	Buy	184,400 +168,200	+1,038%	+$9.63M	﹤0.01%	540
2019 Q3	$22K	Sell	16,200 -33,800	-68%	-$1.59M	﹤0.01%	428
2019 Q2	$271K	Sell	50,000 -2,598,200	-98%	-$121M	0.04%	197
2019 Q1	$4.16M	Buy	+2,648,200	New	+$132M	0.6%	32
2017 Q1	–	Sell	-100,000	Closed	-$15K	–	487
2016 Q4	$15K	Hold	100,000	–	–	﹤0.01%	466
2016 Q3	$254K	Buy	100,000 +85,000	+567%	+$5.46M	0.01%	244
2016 Q2	$2K	Buy	+15,000	New	+$1.06M	﹤0.01%	478
2015 Q2	–	Sell	-120,000	Closed	-$245K	–	457
2015 Q1	$245K	Buy	+120,000	New	+$7.51M	0.02%	356

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bluefin Capital Management's BMY Position: Q1 2026 in Review

Bluefin Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 89% in Q1 2026, selling an estimated $5.08M and leaving 10,300 shares worth $625K. The position accounts for 0.4% of the portfolio, ranked #43.

Bluefin Capital Management first reported a position in BMY in Q2 2013 and has held it in 31 quarters since. The position peaked at $18.3M in Q4 2019. 2,521 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Bluefin Capital Management held 10,300 shares of Bristol-Myers Squibb worth $625K as of Q1 2026.
Bluefin Capital Management sold 87,198 Bristol-Myers Squibb shares in Q1 2026, an estimated $5.08M.
Bristol-Myers Squibb made up 0.4% of Bluefin Capital Management's portfolio in Q1 2026, its #43 holding.
Bluefin Capital Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 31 quarters since.
Bluefin Capital Management's Bristol-Myers Squibb position peaked at $18.3M in Q4 2019.
2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Bluefin Capital Management's 13F filing for Q1 2026, filed 15 May 2026.